Genovis: Updated estimates following acquisition - Redeye

As a follow-up to our initial comment, Redeye updates its estimates and valuation model following yesterday's bolt-on acquisition of KPL ApS. The incorporation has a limited near-term financial impact but adds another meaningful growth avenue over the medium to longer term, further broadening Genovis' enzyme platform into recombinant proteases for LC-MS-based proteomics.

Länk till analysen i sin helhet: https://www.redeye.se/research/1170875/genovis-updated-estimates-following-acquisition?utm_source=finwire&utm_medium=RSS